BCMA-CAR exosomes

BCMA-CAR exosomes are a cell-free immunotherapeutic approach for the treatment of multiple myeloma. These exosomes are derived from BCMA-targeted chimeric antigen receptor (CAR) T-cells and retain the CAR machinery, including the BCMA-specific single-chain variable fragment (scFv), 4-1BB co-stimulatory domain, and CD3ζ signaling domain. By mimicking the tumor-targeting and cytotoxic capabilities of their parent CAR-T cells, these nano-sized vesicles (average diameter ~109 nm) induce dose-dependent lysis of BCMA-expressing myeloma cells and stimulate the release of pro-inflammatory cytokines such as IFN-γ, TNF-α, and IL-2. This approach aims to overcome the manufacturing complexities, high costs, and safety concerns associated with traditional cellular CAR-T therapies.

Other names

BCMA-CAR-T cell-derived exosomesBCMA-targeted CAR exosomes